New England Journal of Medicine Publishes Positive Phase 3 VALOR Trial Results of Brepocitinib in Dermatomyositis

Core Insights - Priovant Therapeutics announced positive results from the Phase 3 VALOR trial for brepocitinib in dermatomyositis, published in the New England Journal of Medicine, indicating significant clinical improvements and potential for practice change in treatment [1][4]. Study Results - The VALOR trial enrolled 241 patients across 90 sites globally, achieving its primary endpoint with brepocitinib 30 mg showing a 15.3-point greater improvement in the Total Improvement Score (TIS) at Week 52 compared to placebo (P<0.001) [2][7]. - Brepocitinib 30 mg demonstrated statistically significant improvements across all nine key secondary endpoints, with effects observable as early as Week 4 and sustained through Week 52 [2][7]. - More than two-thirds of patients on brepocitinib 30 mg achieved a TIS40, which is twice the minimum clinically important difference, while over half reduced systemic corticosteroid use to ≤2.5 mg/day [7]. Safety and Tolerability - Serious infections were more common in the brepocitinib 30 mg group compared to placebo, but these events were manageable, and treatment was completed in most cases [3][8]. - Adverse events leading to treatment discontinuation were more frequent in the placebo group, as were malignancies and cardiovascular events, suggesting that these may reflect the baseline risks associated with dermatomyositis [3][8]. Regulatory Status - The U.S. FDA has granted Priority Review for brepocitinib's New Drug Application (NDA), with a target action date set for the third quarter of 2026 [5][9]. Additional Findings - Analyses presented at the 2026 American Academy of Dermatology Meeting highlighted rapid and statistically significant reductions in itch and improvements in skin-related quality of life for patients treated with brepocitinib [5][6]. - Among patients with moderate-to-severe skin disease at baseline, brepocitinib 30 mg was associated with a 26.6% higher rate of functional skin remission compared to placebo [6]. Company Overview - Priovant Therapeutics focuses on developing novel therapies for autoimmune diseases, with brepocitinib being a first-in-class selective inhibitor of TYK2 and JAK1, targeting key cytokines linked to autoimmunity [10]. - The company is also evaluating brepocitinib in other conditions, including non-infectious uveitis and cutaneous sarcoidosis, with ongoing clinical trials [10]. Parent Company - Roivant is the parent company of Priovant Therapeutics, aiming to accelerate the development and commercialization of impactful medicines across various autoimmune indications [11].